Quantcast
Last updated on April 17, 2014 at 8:56 EDT

Latest Orally disintegrating tablet Stories

2014-02-10 23:20:55

Experts from Catalent Pharma Solution will present ‘Overcoming the Compliance Challenge: Formulation Technology to Improve Acceptance & Adherence’ at the forthcoming Crops & Chemicals Europe Conference. Somerset, NJ (PRWEB) February 10, 2014 Experts from Catalent Pharma Solution will present ‘Overcoming the Compliance Challenge: Formulation Technology to Improve Acceptance & Adherence’ at the forthcoming Crops & Chemicals Europe Conference, Veterinary Medicine:...

2014-01-14 12:27:20

New site to feature proprietary orally disintegrating tablet (ODT) platform, Pharmaburst 500 WILMINGTON, Del., Jan. 14, 2014 /PRNewswire/ -- SPI Pharma is proud to announce the launch of the new Pharmaburst 500 website (www.pharmaburst.com). The new website was designed to assist both R&D formulators and Business Development Managers interested in the development and commercialization of orally disintegrating tablets. The site offers technical resources including starting...

2014-01-14 08:29:14

MIAMI, Jan. 14, 2014 /PRNewswire/ -- Fuisz Pharma announced that it has filed a new patent application with the United States Patent & Trademark Office for a state of the art system, method and kit to obtain blood samples from a finger stick. The blood obtained is greater in volume and includes a system of management of capillary tubes and of obtaining refreshed capillary field blood that more closely approximates the diagnostic gold standard, venous blood, than traditional finger...

2013-07-15 23:16:27

Two poster presentations will be given by Abhijit Gokhale, Ph.D., Senior Scientist, Formulation and Process Development, Patheon Inc., on Monday, July 22 and Tuesday, July 23. (PRWEB) July 15, 2013 Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that the company will showcase its controlled release capabilities and softgel technologies at the 40th Annual Meeting & Exposition of the Controlled...

2013-07-15 16:23:55

PARSIPPANY, N.J., July 15, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, a generic equivalent to GlaxoSmithKline's Lamictal(®) ODT. Actavis intends to launch the product immediately. As a "first applicant" to submit a substantially complete ANDA, Actavis may be...

2013-07-03 12:23:51

BOCA RATON, Fla., July 3, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces the immediate launch of Rizatriptan Benzoate Orally Disintegrating Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA) for this product on July 1, 2013, approximately nine (9) months prior to expiration of the pediatric-exclusivity period for the challenged Orange Book patent (April 1, 2014). Breckenridge's ANDA to...

2013-04-22 08:28:56

MIAMI, April 22, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma today announced its intent to divest its strategic issued patent for the detection of opioid abuse (US 7,214,385 "Pharmaceutical Formulation Containing Dye"). This patent covers the use of dyes and staining agents in pharmaceutical dosage forms as a method to prevent the improper use of opioid drugs by visually demonstrating their misuse and abuse. For example, where a patient abuses a drug like oxycodone through nasal snorting,...

2013-04-18 08:31:46

FALLS CHURCH, Va., April 18, 2013 /PRNewswire/ -- Orally disintegrating tablets (ODTs) are coming into their own as mainstream pharmaceutical products. Oral thin films (OTFs) have also come into strong prominence with the launch of Suboxone® (buprenorphine and naloxone) thin films demonstrating a huge potential for thin films in prescription products. Statistics have shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosages....

2013-01-23 08:28:33

MIAMI, Jan. 23, 2013 /PRNewswire/ -- Fuisz Pharma LLC announced today that it has received a notice of allowance from the United States Patent and Trademark Office in connection with its utility patent application entitled "Solid Dosage Form That Promotes Reliable Oral, Esophageal and GI Transit" (US 20120141545). The allowed claims cover Fuisz Pharma's new tablet and caplet designs for improved transit, including the tablet that Fuisz Pharma calls the "Saturn(TM)". The Saturn(TM) has been...

2013-01-02 12:22:35

WOODCLIFF LAKE, N.J., Jan. 2, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has begun shipping 5 mg and 10 mg strengths of rizatriptan benzoate tablets and 5 mg and 10 mg strengths of rizatriptan benzoate orally disintegrating tablets. Rizatriptan benzoate tablets and rizatriptan benzoate orally disintegrating tablets are each indicated for the acute treatment of migraine with or without aura in adults and in...